A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00639002|
Recruitment Status : Completed
First Posted : March 19, 2008
Results First Posted : January 23, 2012
Last Update Posted : February 13, 2018
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: Ruxolitinib 25 mg Drug: Dexamethasone 40 mg||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma|
|Study Start Date :||March 2008|
|Primary Completion Date :||July 2010|
|Study Completion Date :||July 2010|
Experimental: Ruxolitinib then Ruxolitinib + Dexamethasone
Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion, or withdrew consent, then 40 mg of dexamethasone was added to ruxolitinib on Days 1 to 4, 9 to 12, and 17 to 20 of four 28-day cycles. After the 4th cycle, 40 mg of dexamethasone was administered only on Days 1 to 4 of each subsequent cycle. Patients could continue to receive monotherapy or combination therapy indefinitely as long as no withdrawal criterion was met, did not have progressive disease and were receiving some clinical benefit.
Drug: Ruxolitinib 25 mg
Ruxolitinib was supplied as 5 and 25 mg tablets.
Other Name: INCB018424Drug: Dexamethasone 40 mg
Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
- Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma [ Time Frame: Day 1 of Cycles 2, 3, and 4 and then every 3 months thereafter (up to 25 months). ]A responder is defined as a patient with a complete response (negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow) or a partial response (≥ 50% reduction of serum M-protein and reduction in 24 h urinary M-protein by ≥ 90% or to < 200 mg per 24 h).
- Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma [ Time Frame: Day 1 of Cycles 2, 3, and 4 and then every 3 months thereafter (up to 25 months). ]
Progressive Disease requires 1 or more of the following:
Increase of ≥ 25% from baseline in:
Serum M-component and/or (increase ≥ 0.5 g/dL).
Urine M-component and/or (increase ≥ 200 mg/24 h).
In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels increase must be > l0 mg/dL.
Bone marrow plasma cell percentage ≥ 10%.
Definite development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas.
Development of hypercalcemia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00639002
|United States, California|
|Highland, California, United States, 92346|
|United States, Florida|
|Boynton Beach, Florida, United States, 33435|
|United States, New York|
|New York, New York, United States, 10011|
|Principal Investigator:||Sundar Jagannath, MD||St. Vincent's Comprehensive Cancer Center, New York, New York|